Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

44.84
-2.4100-5.10%
Post-market: 44.910.0700+0.16%19:56 EDT
Volume:7.96M
Turnover:363.93M
Market Cap:7.45B
PE:-12.89
High:47.59
Open:47.38
Low:44.66
Close:47.25
52wk High:86.74
52wk Low:44.66
Shares:166.18M
Float Shares:161.92M
Volume Ratio:1.89
T/O Rate:4.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:16.95
PE(LYR):-18.83

Loading ...

Movement Alert|Ionis Pharmaceuticals Falls 20.03% in Regular Trading, Core Pipeline Drug Eplontersen Fails Phase 3 Cardiac Trial Primary Endpoint

Market Focus
·
Jul 09

Ionis Pharmaceuticals (IONS) Stock Slammed by Phase 3 Trial Results

TIPRANKS
·
Jul 09

Ionis Pharmaceuticals falls -17.6%

TIPRANKS
·
Jul 09

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday as Chip Stocks Rebound Despite US-Iran Tensions

MT Newswires Live
·
Jul 09

Astrazeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction

Dow Jones
·
Jul 09

Ionis Pharmaceuticals Shares Sink After Late-stage Trial Failed to Meet Primary Goal

Dow Jones
·
Jul 09

U.S. Stocks on the Move-levi, Ionis Pharmaceuticals, Gloo Holdings

Reuters
·
Jul 09

S&P 500 Futures Climb in Premarket Trading; Alnylam Pharmaceuticals, Bridgebio Pharma Lead

Dow Jones
·
Jul 09

Schwab Strategists Warn of a Major Market Shift: the Era of Easy Index Gains is Officially Over.

Dow Jones
·
Jul 09

Major Drugmaker Loses $27 Billion in Market Value After Failed Trial

Dow Jones
·
Jul 09

AstraZeneca says CARDIO-TTRansform trial did not meet primary efficacy endpoint

TIPRANKS
·
Jul 09

Tech Rebound Lifts European Shares After Three-day Slide

Reuters
·
Jul 09

Ionis Pharmaceuticals Shares Fall 13.8% Premarket After Drug Made in Partnership with Astrazeneca Fails Late-stage Heart Disease Trial

THOMSON REUTERS
·
Jul 09

Movement Alert|Ionis Pharmaceuticals Falls 14.75% in Pre-Market Trading, Phase 3 ATTR-CM Trial for Eplontersen Fails Primary Endpoint

Market Focus
·
Jul 09

Astrazeneca Top Loser on FTSE 100 After Heart Disease Drug Fails Late-stage Trial

Reuters
·
Jul 09

Astrazeneca Shares Set for Their Biggest One-day Fall Since March 2020

THOMSON REUTERS
·
Jul 09

Astrazeneca Shares Down 9% After Late-stage Trial Miss for Nerve Disease Drug Wainua

THOMSON REUTERS
·
Jul 09

European Shares Gain as Tech Stocks Rebound; Middle East in Focus

Reuters
·
Jul 09

Astrazeneca's Wainua Fails Key Heart Disease Trial, Shares Tumble

Reuters
·
Jul 09

Ionis Says Phase 3 Eplontersen Trial in Attr-cm Misses Primary Endpoint

Reuters
·
Jul 09